Cardio-oncology Related to Heart Failure, An Issue of Heart Failure Clinics. The Clinics: Internal Medicine 7-3

  • ID: 3690111
  • Book
  • 168 Pages
  • Elsevier Health Science
1 of 3

As the number of effective anti-neoplastic agents has grown, there has been a concomitant increase in side effects.  Cardiotoxicity, and specifically LV dysfunction, remains the limiting factor for many such agents, and is the focus of growing research and clinical emphasis.  This issue summarizes for the heart failure specialist the possible ways that chemotherapeutic agents might cause cardiotoxicity as well as the methods for detecting, treating and preventing cardiotoxicity.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Note: Product cover images may vary from those shown
2 of 3


3 of 3
Lenihan, Daniel J. Professor of Medicine, Director, Cardio-Oncology Center of Excellence, Advanced Heart Failure, Clinical Research, Cardiovascular Division, Washington University in St. Louis, St. Louis Missouri.

Sawyer, Douglas B. Maine Medical Center.

Physician-scientist with focus on heart failure leading research and training program developing novel insights into pathophysiology of cardiovascular disease and innovative strategies to prevent and treat advanced heart failure.
Note: Product cover images may vary from those shown
4 of 3
Note: Product cover images may vary from those shown